[HER2低表达状态在原发性和复发性/转移性乳腺癌中的变化]
1Department of Pathology, the Fourth Hospital of Hebei Medical University, Tumor Hospital of Hebei Province, Shijiazhuang 050011, China.
Zhonghua bing li xue za zhi = Chinese journal of pathology
|September 6, 2023
概括
在原发性和转移性乳腺癌之间,HER2表达状态可能会发生变化. 在HER2阴性患者中,HER2的低表达在复发时表明预后有利,并提供更多的治疗选择.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 人体表皮生长因子受体2 (HER2) 是乳腺癌的一个关键生物标志物.
- HER2 阴性是常见的,但其表达可能会演变,特别是在复发性或转移性疾病中.
- 了解HER2状态演变对于定制治疗策略至关重要.
研究的目的:
- 在HER2-阴性患者中,研究从原发性到复发性/转移性乳腺癌中HER2表达的变化.
- 评估在转移性环境中HER2低表达的临床意义和预后价值.
- 确定原发性和复发性/转移性乳腺癌焦点之间的HER2状态的一致率.
主要方法:
- 对259名患有HER2-阴性原发性瘤和复发/转移的乳腺癌患者进行了回顾性分析.
- 在模两可的病例 (IHC 2+) 中,通过免疫组织化学 (IHC) 和光在位杂交 (FISH) 评估HER2状态.
- 根据IHC和FISH结果将HER2归类为HER2-0,HER2低表达和HER2-阳性组.
主要成果:
- 原发性和复发性/转移性部位之间的HER2总体状态一致性为60.6%.
- 很大一部分患者 (39.4%) 显示HER2状态不一致.
- 与剩余的HER2-0 (P<0.05) 相比,患有HER2-0原发性瘤的患者在转移中发展HER2低表达的总体存活时间更长,ER/PR阳性率更高,瘤等级更低.
结论:
- 在原发性和复发性/转移性乳腺癌之间,HER2状态往往不稳定.
- 在转移性部位的HER2低表达,特别是从HER2-0原发性瘤进化时,与良好的预后有关.
- 在复发/转移性疾病中检测HER2状态对于识别有资格接受向治疗的患者至关重要.
更多相关视频
11:34Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
12.7K
08:28Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
172
相关概念视频
Tumor Progression
6.4K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Metastasis
5.6K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.6K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
